Important Safety Information

The CentraSight treatment program uses an implantable medical device - the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) - which is indicated for monocular implant to improve vision in patients with stable severe to profound vision impairment caused by bilateral central scotomas (blind areas) associated with end-stage age-related macular degeneration.

Patients must meet age, vision, cornea health, and other requirements noted in the Patient Information Booklet (pdf).

The most common risks of the telescope implantation surgery include inflammatory deposits or precipitates on the device and increased intraocular pressure. Significant adverse events include corneal edema, corneal decompensation, corneal transplant, and decrease in visual acuity. There is a risk that having the telescope implantation surgery could worsen your vision rather than improve it. Individual results may vary.

These are not all the risks of telescope implantation surgery. Please read the Patient Information Booklet (pdf) to understand the potential risks and benefits of the telescope implant surgery and discuss these with your doctor.

Learn More About Insurance Coverage

If you are a potential candidate for the CentraSight treatment program, a CentraSight Care Manager is available to answer your questions about the treatment and insurance coverage, including Medicare benefits.

Learn more

Have Questions About CentraSight?

Email them to us

The Implantable Miniature Telescope is referred to as "the IMT (by Dr. Isaac Lipshitz)" or as "the Implantable Miniature Telescope (by Dr. Isaac Lipshitz)." Hereinafter, this device may be referred to "the product", "the device", "the telescope", "intraocular telescope", or similar terms which cannot be read as the name of the product. Restricted device: U.S. Federal Law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed practitioner.